Tibet Rhodiola Pharmaceutical Holding

Tibet Rhodiola Pharmaceutical Holding Net Margin

The Net Profit Margin of Tibet Rhodiola Pharmaceutical Holding (600211.SS) as of Oct 18, 2026 is 31.79 %. In the previous year, Net Profit Margin was 37.46 % — a change of -15.13% (lower).

Net Margin

31.79 %

YoY

-15.13%

Last updated:

Net Profit Margin of Tibet Rhodiola Pharmaceutical Holding is 2025 31.79 % . Net Profit Margin of Tibet Rhodiola Pharmaceutical Holding was 2024 37.46 % . It decreases by -15.13% lower compared to the previous year.

Tibet Rhodiola Pharmaceutical Holding's net margin stands at 31.8%, up from 9.8% several years earlier.

The Tibet Rhodiola Pharmaceutical Holding Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
20.98 CNY
Jan 1, 2019
24.87 CNY
Jan 1, 2020
30.45 CNY
Jan 1, 2021
9.77 CNY
Jan 1, 2022
14.48 CNY
Jan 1, 2023
25.55 CNY
Jan 1, 2024
37.46 CNY
Jan 1, 2025
31.79 CNY
The Tibet Rhodiola Pharmaceutical Holding Net Margin history
YEARNet MarginYoY
31.79 %-15.13%
37.46 %+46.58%
25.55 %+76.50%
14.48 %+48.18%
9.77 %-67.91%
30.45 %+22.45%
24.87 %+18.55%
20.98 %-16.37%
25.08 %+0.78%
24.89 %+275.51%
6.63 %+426.89%
1.26 %+6,395.21%
0.02 %-22.53%
0.02 %+31.48%
0.02 %-10.36%
0.02 %+16.48%
0.02 %+178.20%
0.01 %-104.30%
-0.15 %-3,308.83%
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Tibet Rhodiola Pharmaceutical Holding Stock analysis

What does Tibet Rhodiola Pharmaceutical Holding do? Tibet Rhodiola Pharmaceutical Holding Co, listed on the Shanghai Stock Exchange under ticker 600211.SS, operates as a pharmaceutical company based in Lhasa, China. The company's ISIN is CNE000000ZW7. Founded through an IPO on July 21, 1999, it specializes in the manufacture and wholesale of pharmaceutical products. Its headquarters are located in Lhasa, Xizang, and it employs 615 full-time staff. The firm distributes proprietary drug products and processes pharmaceuticals, conducting business primarily across South China, North China, East China, Central China, and overseas markets. The company's website is http://www.xzyy.cn. It does not provide details on specific products, acquisitions, or financial figures beyond the IPO date and employee count. The company focuses on pharmaceutical manufacturing and distribution within its operational regions, with no additional information provided on its product lines or market share. Tibet Rhodiola Pharmaceutical Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Rhodiola Pharmaceutical Holding stock

Net Profit Margin of Tibet Rhodiola Pharmaceutical Holding is 31.79 % in 2025.

Net Profit Margin of Tibet Rhodiola Pharmaceutical Holding changed from 37.46 % to 31.79 %, representing a -15.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Tibet Rhodiola Pharmaceutical Holding since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Tibet Rhodiola Pharmaceutical Holding with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Tibet Rhodiola Pharmaceutical Holding

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Tibet Rhodiola Pharmaceutical Holding